As debate rages over adoption of biosimilars in the U.S., a new analysis finds that 17 of the largest commercial health plans last year rarely preferred these versions of brand-name biologics when crafting coverage decisions.

Specifically, the insurers made 535 coverage decisions last year for nine biosimilars that were available in the U.S. But the health plans required patients first try a biosimilar before gaining access to a brand-name biologic just 14% of the time. By contrast, brand-name medicines were favored in 33% of the coverage decisions, while preferred coverage was offered for both medicines 53% of the time.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • one issue is that biosimilar developers and marketers came into this expecting they could still rake in lots of $$ without major discounts. that’s understandable given they need to spend the time and money to do large clinical trials (unlike traditional generics). they thought they could take the market with just a 15-20% discount over the brand price, but J&J (for example) isn’t about to give up a billions of dollars without a fight. They just rebate to match these relatively minor discounts. Doctors and patients aren’t comfortable switching patients already on the brand (which brands spent years and lots of $$ ensuring), which gives the brand companies more leverage. The answer is price. Will J&J match a 50% discount? How about 60%? I heard that Norway or another Scandinavian country negotiated a 70+% discount for a biosimilar back in 2006 or so. But that’s not the business model biosimilars built there products around…

  • uhhh, you do realize that biologics are large molecule and all are injectables, not orals, right? The choice of art to accompany the article paints Stat in a poor light.

  • May I observe that I recognize this estimate – “they could have saved an average of $1.5 million and their employees would also have spent hundreds of dollars less.” It has been used here before, but some a savings of $1.5 million / year doesn’t sound like a great deal – to the working / even middle class, definitely, but in the corporate framework?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy